Revenue
2008
2009
2010
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Alnylam Pharmaceuticals, Inc. (ALNY)
Price$175.82Cached quote
Net income
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.71B | $2.25B | $1.83B | $1.04B | $844.3M | $492.9M | $219.8M | $74.9M | $89.9M | $47.2M | — | — | — | — | — | $100.0M | $100.5M | $96.2M |
| Gross profit | $3.04B | $1.94B | $1.56B | $897.2M | $729.3M | $418.7M | $194.7M | $73.1M | $89.9M | — | — | — | — | — | — | — | — | — |
| Gross margin | 81.77% | 86.37% | 85.33% | 86.49% | 86.38% | 84.95% | 88.60% | 97.59% | 100.00% | — | — | — | — | — | — | — | — | — |
| Research & development | $1.32B | $1.13B | $1.00B | $883.0M | $792.2M | $654.8M | $655.1M | $505.4M | $390.6M | $382.4M | $276.5M | $190.2M | $113.0M | $86.6M | $99.3M | $106.4M | $108.7M | $96.9M |
| Operating expenses | $2.54B | $2.12B | $1.84B | $1.68B | $1.44B | $1.25B | $1.13B | $887.8M | $590.0M | $471.7M | $337.1M | $455.5M | $140.1M | $196.2M | $137.6M | $144.1M | $148.6M | $124.0M |
| Operating income | $501.6M | −$176.9M | −$282.2M | −$785.1M | −$708.7M | −$828.4M | −$939.4M | −$814.7M | −$500.1M | −$424.6M | −$296.0M | −$405.0M | −$92.9M | −$129.5M | −$54.8M | −$44.1M | −$48.1M | −$27.8M |
| Operating margin | 13.51% | −7.87% | −15.43% | −75.68% | −83.93% | −168.09% | −427.50% | −1,087.56% | −556.20% | −900.33% | — | — | — | — | — | −44.05% | −47.86% | −28.95% |
| EBITDA | $557.2M | −$120.2M | −$228.1M | −$740.6M | −$661.1M | −$793.7M | −$922.3M | −$799.4M | −$486.7M | −$409.5M | −$277.0M | −$393.1M | −$82.7M | −$120.4M | −$49.7M | −$39.1M | −$42.1M | −$22.1M |
| EBITDA margin | 15.00% | −5.35% | −12.48% | −71.39% | −78.30% | −161.04% | −419.68% | −1,067.21% | −541.33% | −868.25% | — | — | — | — | — | −39.11% | −41.90% | −22.99% |
| Net income | $313.7M | −$278.2M | −$440.2M | −$1.13B | −$852.8M | −$858.3M | −$886.1M | −$761.5M | −$490.9M | −$410.1M | −$290.1M | −$360.4M | −$89.2M | −$106.0M | −$57.6M | −$43.5M | −$47.6M | −$26.2M |
| Net profit margin | 8.45% | −12.37% | −24.08% | −109.04% | −101.01% | −174.15% | −403.24% | −1,016.58% | −545.95% | −869.63% | — | — | — | — | — | −43.50% | −47.34% | −27.30% |
| Basic EPSper basic share | $2.39 | -$2.18 | -$3.52 | -$9.30 | -$7.20 | -$7.46 | -$8.11 | -$7.57 | -$5.42 | -$4.79 | -$3.45 | -$4.85 | -$1.45 | -$2.11 | -$1.36 | -$1.04 | -$1.14 | — |
| Diluted EPSper diluted share | $2.33 | -$2.18 | -$3.52 | -$9.30 | -$7.20 | -$7.46 | -$8.11 | -$7.57 | -$5.42 | -$4.79 | -$3.45 | -$4.85 | -$1.45 | -$2.11 | -$1.36 | -$1.04 | -$1.14 | — |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Greenstreet Yvonne | 96.21K |
Poulton Jeffrey V. | 61.86K |
Tanguler Tolga | 34.3K |
SCHULMAN AMY W | 24.05K |
Fitzgerald Kevin Joseph | 21.11K |
Garg Pushkal | 19.37K |
SUPRAN BRYAN | 14.57K |
McLaughlin Melissa | 9.44K |
Hesslein Robert W. | 8K |
Ausiello Dennis A | 5.08K |
Sigal Charles Elliott | 3.45K |
HAMBURG MARGARET A | 1.58K |
KELLOGG PETER N | 1.45K |
BRANDICOURT OLIVIER | 1.45K |
Reitan Colleen F | 1.45K |
Bertozzi Carolyn R | 775 |
Arbuckle Stuart A | 671 |
PYOTT DAVID E I | — |
BONNEY MICHAEL W | — |
SHARP PHILLIP A | — |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 4 ↗Updated Oct 21, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 1, 2026Form 4 · 10b5-1 | PYOTT DAVID E IDirector | SellCommon Stock | 17 | $302.65 | $5.1K | 1.6K |
| Jun 1, 2026Form 4 · 10b5-1 | PYOTT DAVID E IDirector | SellCommon Stock | 495 | $300.72 | $148.9K | 1.6K |
| Jun 1, 2026Form 4 · 10b5-1 | PYOTT DAVID E IDirector | SellCommon Stock | 1.2K | $299.87 | $366.4K | 2.1K |
| Jun 1, 2026Form 4 · 10b5-1 | PYOTT DAVID E IDirector | SellCommon Stock | 1.2K | $298.91 | $351.2K | 3.3K |
| Jun 1, 2026Form 4 · 10b5-1 | PYOTT DAVID E IDirector | SellCommon Stock | 921 | $297.71 | $274.2K | 4.5K |
Community posts
Alnylam’s product sales jump 52% as it enlarges a pivotal heart-disease trial
Alnylam ($ALNY) reported third-quarter 2026 product revenue of $1.29 billion, up 52%, led by Amvuttra and Onpattro’s combined $1.15 billion contribution. Total revenue increased a slower 17% to $1.46 billion because collaboration revenue de ...
